

Research

Open Access

## A role of p38 mitogen-activated protein kinase in adenosine A<sub>1</sub> receptor-mediated synaptic depotentiation in area CA1 of the rat hippocampus

Ying-Ching Liang<sup>2</sup>, Chiung-Chun Huang<sup>1</sup> and Kuei-Sen Hsu<sup>\* 1,2</sup>

Address: <sup>1</sup>Department of Pharmacology, College of Medicine, National Cheng Kung University, No. 1, University Road, Tainan City 701, Taiwan and <sup>2</sup>Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, No. 1, University Road, Tainan City 701, Taiwan

Email: Ying-Ching Liang - [alice217@ms35.url.com.tw](mailto:alice217@ms35.url.com.tw); Chiung-Chun Huang - [Chun19680111@yahoo.com.tw](mailto:Chun19680111@yahoo.com.tw); Kuei-Sen Hsu\* - [richard@mail.ncku.edu.tw](mailto:richard@mail.ncku.edu.tw)

\* Corresponding author

Published: 23 October 2008

Received: 2 September 2008

*Molecular Brain* 2008, 1:13 doi:10.1186/1756-6606-1-13

Accepted: 23 October 2008

This article is available from: <http://www.molecularbrain.com/content/1/1/13>

© 2008 Liang et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### Abstract

**Background:** Although long-term potentiation (LTP) of synaptic strength is very persistent, current studies have provided evidence that various manipulations or pharmacological treatment when applied shortly after LTP induction can reverse it. This kind of reversal of synaptic strength is termed as depotentiation and may have a function to increase the flexibility and storage capacity of neuronal networks. Our previous studies have demonstrated that an increase in extracellular levels of adenosine and subsequent activation of adenosine A<sub>1</sub> receptors are important for the induction of depotentiation; however, the signaling downstream of adenosine A<sub>1</sub> receptors to mediate depotentiation induction remains elusive.

**Results:** We confirm that depotentiation induced by low-frequency stimulation (LFS) (2 Hz, 10 min, 1200 pulses) was dependent on adenosine A<sub>1</sub> receptor activation, because it was mimicked by bath-applied adenosine A<sub>1</sub> receptor agonist N<sup>6</sup>-cyclopentyladenosine (CPA) and was inhibited by the selective adenosine A<sub>1</sub> receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine (DPCPX). Pretreatment of the hippocampal slices with the selective p38 mitogen-activated protein kinase (MAPK) inhibitors, 4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole (SB203580) or *trans*-1-(4-hydroxycyclohexyl)-4-(fluorophenyl)-5-(2-methoxy-pyrimidin-4-yl)imidazole (SB239063), prevented the induction of depotentiation by LFS and CPA. In agreement with electrophysiological observation, both LFS- and CPA-induced depotentiation are associated with an increase in p38 MAPK activation, which are blocked by DPCPX or SB203580 application.

**Conclusion:** These results suggest that activation of adenosine A<sub>1</sub> receptor and in turn triggering p38 MAPK signaling may contribute to the LFS-induced depotentiation at hippocampal CA1 synapses.

### Background

Long-term potentiation (LTP) is a long-lasting form of activity-dependent synaptic plasticity that is generally

thought to play crucial roles in learning and memory processes in the brain [1,2]. Although LTP is remarkable for its stability, numerous studies have revealed that it is

initially labile and sensitive to disruption by a variety of interfering events and agents [3,4]. Such reversal of synaptic strength from the potentiated state to pre-LTP levels has been termed depotentiation and may provide a mechanism of preventing the saturation of the synaptic potentiation and increase the efficacy and the capacity of the information storage of the neuronal networks [3].

A sustained train of low-frequency stimulation (LFS) is a powerful paradigm for studying the molecular mechanism underlying the induction of depotentiation. Previous work from our and other laboratories have demonstrated that trains of 1–5 Hz LFS can produce an enduring and complete reversal of synaptic potentiation when delivered within 10 min of LTP induction [1,3,5,6]. So far, a number of synaptic signaling molecules have been identified that participates in the induction of depotentiation including adenosine, calcineurin, nitric oxide, and small GTPase Rap2 [6–12]. Less well understood are the processes that control signaling from these synaptic ligands and receptors. For example, we have previously proposed that the reversal of LTP at the Schaffer collateral-CA1 synapses by LFS is associated with an increase of extracellular levels of adenosine acting on adenosine A<sub>1</sub> receptor to interrupt the cAMP/protein kinase A (PKA)-dependent biochemical processes leading to LTP [6,11]. We further demonstrated that the efflux of cAMP is the potential source for the increased extracellular adenosine underlying LFS-induced depotentiation [6]. However, it is still unclear the signaling downstream of adenosine A<sub>1</sub> receptors to mediate the induction of LFS-induced depotentiation. Recent data suggest that p38 mitogen-activated protein kinase (MAPK) activation may contribute to adenosine A<sub>1</sub> receptor-mediated synaptic depression in the hippocampal CA1 region [13]. Moreover, p38 MAPK signaling has been shown to be an important mediator of AMPA receptor surface trafficking during synaptic plasticity, a process crucial for rapid altering synaptic strength [14,15]. It became, therefore, of interest to study possible roles of p38 MAPK in adenosine A<sub>1</sub> receptor-mediated depotentiation.

Here, we tested whether p38 MAPK signaling is involved in the induction of LFS-induced depotentiation in the CA1 region of hippocampus. Our study provides evidence that p38 MAPK may serve as a signaling downstream of adenosine A<sub>1</sub> receptor activation to induce depotentiation.


## Results

### **p38 MAPK contributes to LFS-induced depotentiation**

Using field potential recordings, we first tested for the existence of a LFS-induced depotentiation in the CA1 region of hippocampal slices. LTP was induced by two 1-sec trains of 100 Hz stimuli separated by intertrain inter-

val of 20 sec. The mean slope of the field excitatory postsynaptic potential (fEPSP) measured 50 min after high-frequency tetanic stimulation (HFS) was  $146.5 \pm 4.2\%$  ( $n = 8$ ) of baseline (Fig. 1A). To establish a reliable depotentiation, a long train of LFS protocol, 2 Hz/1200 pulse stimulation, was used [6,16]. As expected, when LFS was applied 5 min after LTP induction, LTP was almost completely reversed (Fig. 1A). The mean residual potentiation measured 40 min after the end of LFS was  $96.5 \pm 5.8\%$  ( $n = 8$ ) of baseline. Thus, these results generally confirmed previous studies showing that LTP is vulnerable to disruption by depotentiation stimuli within a short period after its induction [6,17,18].

To assess the role of p38 MAPK in the induction of LFS-induced depotentiation, the highly selective p38 MAPK inhibitor 4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole (SB203580) was used. As shown in Figure 1B, SB203580 (1  $\mu$ M) treatment alone had no effect on the induction of LTP. The mean slope of the fEPSP measured 50 min after HFS was  $153.6 \pm 8.5\%$  ( $n = 6$ ) of baseline, which was not statistically different from the corresponding values of control slices. In marked contrast to control slices, application of LFS, 5 min after LTP induction, failed to induce depotentiation in all eight slices tested. The mean residual potentiation measured 40 min after the end of LFS was  $138.5 \pm 6.2\%$  ( $n = 8$ ) of baseline (Fig. 1B). To further confirm a role of p38 MAPK in the induction of depotentiation, in another set of experiments, we examined the effect of another p38 MAPK inhibitor *trans*-1-(4-hydroxycyclohexyl)-4-(fluorophenyl)-5-(2-methoxy-pyrimidin-4-yl)imidazole (SB239063) on the LFS-induced depotentiation. We found that application of SB239063 (1  $\mu$ M) failed to affect the LTP induction ( $148.5 \pm 8.1\%$  of baseline,  $n = 4$ ;  $p > 0.05$  when compared with control LTP slices; unpaired Student's *t* test), but prevented the LFS-induced depotentiation (Fig. 1C). The mean residual potentiation measured 40 min after the end of LFS was  $139.5 \pm 7.5\%$  ( $n = 5$ ) of baseline. In addition, in both control and SB203580-treated slices, 10 min of 2 Hz stimulation delivered to Schaffer collateral-CA1 synapses had no long-lasting effect on the synaptic transmission (Fig. 1D). The mean slope of the fEPSP measured 40 min after the end of LFS was  $96.5 \pm 6.7\%$  ( $n = 6$ ) and  $98.3 \pm 7.2\%$  ( $n = 6$ ) of baseline, respectively. Similar results were also obtained using an antibody that selectively recognizes phosphorylated, activated p38 MAPK [19]. As shown in Figure 1E, phospho-p38 MAPK was readily detected in untreated control slices, and the levels were increased to  $132.5 \pm 6.8\%$  ( $n = 5$ ) of control in LFS (2 Hz)-treated slices. However, no significant changes in the levels of phospho-p38 MAPK were observed 30 min after LTP induction ( $102.8 \pm 5.6\%$  of control slices,  $n = 5$ ;  $p > 0.05$ ; unpaired Student's *t* test). In LFS-induced depotentiation experiments, we found that there was signifi-



**Figure 1** (see legend on next page)

**Figure 1** (see previous page)

**p38 MAPK contributes the induction of LFS-induced depotentiation.** (A) Summary of experiments showing that LFS (2 Hz, 10 min) given 5 min after two trains of 100 Hz HFS almost completely reversed LTP ( $n = 8$ ; ○), whereas fEPSPs in slices that received HFS without LFS exhibited persistent potentiation ( $n = 8$ ; ●). (B) Summary of experiments showing that pretreatment of slices with the p38 MAPK inhibitor SB203580 (1  $\mu\text{M}$ ) blocked the induction of LFS-induced depotentiation ( $n = 8$ ; ●) but had no effect on the induction of LTP ( $n = 6$ ; ○). (C) Summary of experiments showing that pretreatment of slices with the p38 MAPK inhibitor SB239063 (1  $\mu\text{M}$ ) blocked the induction of LFS-induced depotentiation ( $n = 5$ ; ●) but had no effect on the induction of LTP ( $n = 4$ ; ○). (D) Summary of experiments showing that the protocol of LFS had no lasting effect on synaptic transmission in the presence of vehicle ( $n = 6$ ; ○) or SB203580 ( $n = 6$ ; ●). The superimposed fEPSP in the inset illustrates respective recordings from example experiments taken at the time indicated by number. Horizontal bars denote the period of delivery LFS or SB203580. (E) Representative immunoblots showing that the induction of LFS-induced depotentiation (DEP) is accompanied by a significant increase in p38 MAPK phosphorylation and that SB203580 (1  $\mu\text{M}$ ) prevented this enhancement action. Group data showing the normalization of phospho-p38 MAPK to the nonphosphorylated form was determined in each group of five experiments. In each experiment, 21–28 slices obtained from 2–3 rats were used. \*,  $p < 0.05$  (unpaired Student's  $t$  test) as compared with the control (Con) group.

cant increased the levels of phospho-p38 MAPK ( $134.2 \pm 7.2\%$  of control slices,  $n = 5$ ;  $p < 0.05$ ; unpaired Student's  $t$  test). In addition, pretreatment of the slices with SB203580 (1  $\mu\text{M}$ ) completely blocked the increase in p38 MAPK phosphorylation induced by LFS (Fig. 1E). These results strongly support the view that the p38 MAPK is an obligatory component of the biochemical bases that serves the induction of LFS-induced depotentiation.

#### **Adenosine A<sub>1</sub> receptor-mediated depotentiation was decreased by p38 MAPK inhibition**

We and other laboratories have previously shown that an increase of extracellular adenosine acting on adenosine A<sub>1</sub> receptors may be a component of the mechanism that triggers LFS-induced depotentiation in the hippocampal CA1 region [6,8,18]. A recent study has revealed that adenosine A<sub>1</sub> receptor-mediated synaptic depression is dependent on p38 MAPK activation [13]. It was therefore of interest to examine the relationship between p38 MAPK activation and adenosine-mediated signaling pathways in the induction of depotentiation. We began by confirming that LFS-induced depotentiation can be blocked by the selective adenosine A<sub>1</sub> receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine (DPCPX). As shown in Figure 2A, the LFS-induced depotentiation was significantly inhibited in the presence of DPCPX (0.1  $\mu\text{M}$ ). The slope of fEPSP after LFS recovered close to the initial LTP levels. The mean residual potentiation measured 40 min after the end of LFS was  $140.9 \pm 8.6\%$  ( $n = 5$ ) of baseline. Application of DPCPX alone had no significant effect on the induction of LTP ( $149.7 \pm 7.5\%$  of baseline,  $n = 6$ ;  $p > 0.05$ ; unpaired Student's  $t$  test).

We next tested whether the reversal of LTP induced by a direct adenosine application was also affected by p38 MAPK antagonism. Because adenosine may act at multiple receptor subtypes and is rapidly degraded by ectonucleotidases [20], we used the specific adenosine A<sub>1</sub>

receptor agonist N<sup>6</sup>-cyclopentyladenosine (CPA) to address this issue. Application of CPA (0.2  $\mu\text{M}$ ) for 5 min potentially depressed the fEPSP by  $84.5 \pm 6.5\%$  of baseline ( $n = 6$ ). The fEPSP fully recovered after washout of drug (Fig. 2B). We next examined the effect of CPA application on the previously established LTP. In agreement with our previous findings [6,11], CPA (0.2  $\mu\text{M}$  for 5 min) applied 5 min after LTP induction almost completely reversed LTP (Fig. 2C). The mean residual potentiation measured 40 min after washout of CPA was  $98.9 \pm 7.2\%$  ( $n = 6$ ) of baseline. When CPA was applied in the presence of DPCPX (0.1  $\mu\text{M}$ ), both acute response and the resulting depotentiation were inhibited significantly (Fig. 2C). The mean residual potentiation measured 40 min after washout of CPA was  $142.3 \pm 6.5\%$  ( $n = 6$ ) of baseline. In addition, we tested the effect of SB203580 and SB239063 on the induction of depotentiation by CPA. As shown in Figure 2D, treatment of either SB203580 (1  $\mu\text{M}$ ) or SB239063 (1  $\mu\text{M}$ ) had little effect on the acute response during CPA application but significantly blocked the induction of CPA-induced depotentiation. The mean residual potentiation measured 40 min after washout of CPA was  $136.5 \pm 6.7\%$  ( $n = 6$ ) and  $132.3 \pm 7.4\%$  ( $n = 4$ ) of baseline, respectively. In addition, pretreatment of the slices with DPCPX (0.1  $\mu\text{M}$ ) completely blocked the increase in p38 MAPK phosphorylation induced by LFS (Fig. 2E). Figure 2F shows that substantial increase in the levels of phospho-p38 MAPK is evident in CPA-induced depotentiation slices. Pretreatment of either DPCPX (0.1  $\mu\text{M}$ ) or SB203580 (1  $\mu\text{M}$ ) for 20 min also blocked the increase in p38 MAPK phosphorylation induced by CPA. Together, these results suggest that p38 MAPK seems to be the downstream signaling molecule for adenosine A<sub>1</sub> receptor activation to induce depotentiation.

#### **Discussion**

In this study, we identify a novel interaction between adenosine A<sub>1</sub> receptor and p38 MAPK in hippocampal neu-




Figure 2 (see legend on next page)

**Figure 2** (see previous page)

**Application of p38 MAPK inhibitor prevented the induction of adenosine A<sub>1</sub> receptor-mediated depotentiation.** (A) Summary of experiments showing that pretreatment of slices with the adenosine A<sub>1</sub> receptor antagonist DPCPX (0.1 μM) blocked the induction of LFS-induced depotentiation (n = 5; ●) but had no effect on the induction of LTP (n = 6; ○). (B) Summary of experiments showing that application of CPA (0.2 μM) for 5 min produced a depression of fEPSPs (n = 6; ○). The fEPSP fully recovered after washout of drug. (C) Summary of experiments showing that CPA (0.2 μM; 5 min) given 5 min after two trains of 100 Hz HFS almost completely reversed LTP (n = 6; ○). Note that CPA-induced depotentiation was completely blocked by DPCPX (n = 6; ●). (D) Summary of experiments showing that pretreatment of slices with SB203580 (1 μM, n = 6; ○) or SB239063 (1 μM, n = 4; ●) blocked the CPA-induced depotentiation. (E) Representative immunoblots showing that the induction of LFS-induced depotentiation (DEP) is accompanied by a significant increase in p38 MAPK phosphorylation and that DPCPX prevented this enhancement action. Group data showing the normalization of phospho-p38 MAPK to the non-phosphorylated form was determined in each group of four experiments. In each experiment, 21–28 slices obtained from 2–3 rats were used. (F) Representative immunoblots showing that the induction of CPA-induced depotentiation (CPA-DEP) is accompanied by a significant increase in p38 MAPK phosphorylation. Note that CPA-induced increase in p38 MAPK phosphorylation was significantly blocked by DPCPX or SB203580. Group data showing the normalization of phospho-p38 MAPK to the nonphosphorylated form was determined in each group of five experiments. In each experiment, 15–20 slices obtained from 2 rats were used. \*, p < 0.05 (unpaired Student's t test) as compared with the control (Con) group.

rons. We have shown that activation of adenosine A<sub>1</sub> receptors, either by a train of LFS or a brief application of adenosine A<sub>1</sub> receptor agonist CPA, can trigger a depotentiation by a mechanism that requires the activation of p38 MAPK signaling pathway.

A number of studies have revealed an important role for extracellular adenosine acting on adenosine A<sub>1</sub> receptors in mediating the induction of depotentiation [6,8,11,18]. However, the signaling downstream of adenosine A<sub>1</sub> receptor activation to trigger depotentiation remains elusive. We have previously shown that activation of adenosine A<sub>1</sub> receptor may interrupt the cAMP-PKA-dependent biochemical processes associated with the LTP expression [6,11]. Here, we have extended these findings by demonstrating that p38 MAPK may lie downstream of adenosine A<sub>1</sub> receptor activation to induce depotentiation. Evidence supporting this prediction is that pretreatment of the hippocampal slices with the specific p38 MAPK inhibitors, SB203580 and SB239063, effectively prevented the induction of depotentiation by LFS and CPA. We further show that the induction of LFS- or CPA-induced depotentiation also led to a significant increase in the levels of p38 MAPK phosphorylation and these effects were prevented by prior treatment of the hippocampal slices with adenosine A<sub>1</sub> receptor antagonist. Such a result is in line with the recent observation that p38 MAPK activation contributes to adenosine A<sub>1</sub> receptor-mediated synaptic depression at Schaffer collateral-CA1 synapses [13].

The induction and expression of depotentiation involve multiple cellular and molecular mechanisms [3,4]. A number of studies indicate that the induction of depotentiation relies on synaptic activation of NMDA receptors [5,11,21] or metabotropic glutamate (mGlu) receptors [22–24]. We have previously shown that hippocampal

CA1 depotentiation induced by LFS (2 Hz, 10 min, 1200 pulses) is dependent on NMDA receptor activation [11]. We further showed that activation of NMDA receptors may stimulate adenosine-mediated signaling pathways to trigger depotentiation [11]. In this study, we have extended these findings by showing that p38 MAPK could act downstream of adenosine A<sub>1</sub> receptor activation to undergo the induction of depotentiation. The role of mGlu receptors in the induction of depotentiation remains controversial, largely because some groups have been unable to replicate the findings that mGlu receptors are necessary for depotentiation induction under their experimental conditions [25]. The reason for this discrepancy is not clear but could be attributable partly to the use of different depotentiating stimulation protocols. Because the ability of LFS used in the present study to erase LTP was not significantly affected by either non-selective mGlu antagonist α-methyl-4-carboxyphenylglycine (MCPG) or selective group 1 mGlu receptor antagonist 2S-2-amino-2-(1S,2S-2-carboxycycloprop-1-yl)-3-(xanth-9-yl)-propanoic acid (LY341495) treatment (Huang and Hsu unpublished observation), we suggest that the activation of mGlu receptors is not required for the LFS-induced depotentiation in the hippocampal CA1 region.

How might adenosine A<sub>1</sub> receptors stimulation lead to p38 MAPK activation? The signal transduction events that couple adenosine A<sub>1</sub> receptor stimulation to p38 MAPK activation were not examined here. A previous study in the smooth muscle cell line has indicated that p38 MAPK can be activated by the adenosine A<sub>1</sub> receptors via a pertussis toxin-sensitive signaling pathway [26]. It seems likely that the p38 MAPK activation by the adenosine A<sub>1</sub> receptors is mediated by G<sub>i/o</sub> proteins coupling to classical intracellular signaling pathways such as modulation of cAMP production or the phospholipase C pathway

[27,28]. Interestingly, several other studies have reported that G protein-coupled receptors can also activate p38 MAPK via G $\beta\gamma$  subunits. For example, in human embryonic kidney 293 cells, G $_i$ -coupled m2 muscarinic receptors and G $_s$ -coupled  $\beta$ -adrenergic receptors were found to stimulate p38 MAPK via G $\beta\gamma$  [29]. Similarly, our previous study has also demonstrated that by releasing G $\beta\gamma$  subunits, the G $_{q/11}$ -coupled type 5 metabotropic glutamate receptors can activate small GTPase Rap1 to mediate (S)-3,5-dihydroxyphenylglycine (DHPG)-induced p38 MAPK activation in hippocampal CA1 neurons [15]. According to these previous observations, it will be important for future studies to identify which of these mechanisms is responsible for the adenosine A $_1$  receptor-mediated p38 MAPK activation observed in hippocampal CA1 neurons.

How might p38 MAPK activation reverse the previously established LTP? A most likely possibility is that a decrease in the surface expression of AMPA receptors contributes to this process. Activity-dependent changes in AMPA receptor trafficking have been proposed to play a critical role in mediating bidirectional synaptic plasticity [30,31]. It has been shown that LTP induction in hippocampal slices is associated with an increase in the delivery of AMPA receptors to dendritic spines [32,33], whereas the expression of LTD is associated with a decrease in the surface expression of AMPA receptors [34,35]. With the use of biochemical surface biotinylation assay, we have previously shown that the expression of DHPG-induced depotentiation is associated with a reduction in the increase of the surface expression of AMPA receptors seen with LTP [24]. This finding strongly implies that the removal of synaptic surface AMPA receptor is a potential mechanism underlying the expression of depotentiation in hippocampal neurons. In addition, previous work from our and other laboratories has demonstrated that activation of p38 MAPK may lead to synaptic removal of surface AMPA receptors [12,15]. These results suggest that p38 MAPK-mediated synaptic removal of surface AMPA receptors may account for, at least in part, the development of adenosine A $_1$  receptor-dependent form of depotentiation. Our previous studies have found that the expression of LFS-induced depotentiation was accompanied by a persistent dephosphorylation of the GluR1 subunit of AMPA receptors at serine 831, a protein kinase C and calcium/calmodulin-dependent protein kinase II substrate, but not at serine 845, a substrate of PKA [6,11]. Activation of protein phosphatase 1 (PP1) triggered this dephosphorylation (Huang et al., 2001) and inhibition of PP1 activity rendered the depotentiation stimuli ineffective [6,36]. Taken together, these findings indicate that the interaction between p38 MAPK and PP1 can determine whether depotentiation is induced at Schaffer collateral-CA1 synapses.

Our results indicate that SB203580 produced only little effect on the acute response during CPA application but significantly blocked the induction of CPA-induced depotentiation. This finding is in contrast with observation made in a previous study [13], which reported that SB203580 potently reduced CPA-mediated synaptic depression. The reason for this discrepancy is not clear. It remains to be determined if the use of different concentrations of CPA (0.2  $\mu$ M vs. 40 nM) and SB203580 (1  $\mu$ M vs. 25  $\mu$ M) has a role in explaining the conflicting results. In addition, SB203580 has been shown to effectively compete the binding of adenosine A $_1$  receptor antagonist DPCPX in rat brain membrane at micromolar concentrations [37]. Given that the concentration of SB203580 used in this study was below the effective concentration as adenosine A $_1$  receptor antagonist [37], we therefore assumed that the effect of SB203580 on depotentiation was mediated via the inhibition of p38 MAPK.

An intriguing observation of this study is that 2 Hz stimulation alone in control slices significantly increased the levels of phospho-p38 MAPK but had no long-lasting effect on the basal synaptic transmission (Fig. 1D, 1E and 2E). A plausible explanation for this finding may be that p38 MAPK activity is required but is not sufficient for the induction of synaptic depotentiation or depression. However, further experiments are required to test this possibility.

## Conclusion

In summary, we have shown in this study that p38 MAPK is activated by adenosine A $_1$  receptor stimulation and contributes to the induction of depotentiation in the hippocampal CA1 region. Given the potential role of LTP in learning and memory formation and the processes disrupting the formation of stable LTP may be the possible cause for the loss of memory [1,3], our findings imply a possibility that p38 MAPK is a potential common signaling molecule to exert the mechanism of memory loss. It would be interesting to explore whether the selective p38 MAPK inhibitor may be implicated in enhancing cognition in the treatment of some dementia disorders.

## Methods

### Hippocampal slice preparation

All procedures were performed according to NIH guidelines for animal research (Guide for the Care & Use of Laboratory Animals, NRC, 1996) and approved by the Institutional Animal Care and Use Committee at National Cheng Kung University. Hippocampal slices were obtained from 28- to 35-day old young male Sprague-Dawley rats for extracellular recordings by the procedures described previously [6]. In brief, animals were anesthetized with halothane and decapitated with guillotine, and the hippocampi were removed, placed in ice cold artificial

CSF (aCSF) solution and cut with a Leica VT1000S tissue slicer (Leica, Nussloch, Germany) into transverse slices of 400  $\mu\text{m}$ . After their preparation, slices were placed in a holding chamber of aCSF oxygenated with 95%  $\text{O}_2$ -5%  $\text{CO}_2$  and kept at room temperature for at least 1 h before used. The composition of the aCSF solution was (in mM): NaCl 117, KCl 4.7,  $\text{CaCl}_2$  2.5,  $\text{MgCl}_2$  1.2,  $\text{NaHCO}_3$  25,  $\text{NaH}_2\text{PO}_4$  1.2 and glucose 11 at pH 7.3–7.4 and equilibrated with 95%  $\text{O}_2$ -5%  $\text{CO}_2$ .

### **Electrophysiological recordings**

For the extracellular field potential recordings, a single slice was transferred to a submerge-type recording chamber and held between two nylon nets. The chamber consisted of a circular well of a low volume (1–2 ml) and was continuously perfused with oxygenated aCSF at a flow rate of 2–3 ml/min at  $32.0 \pm 0.5^\circ\text{C}$ . Area CA3 was surgically removed after sectioning. Extracellular field potential recordings were carried out using an Axoclamp-2B amplifier (Axon Instruments, Union City, CA). Microelectrodes were pulled from microfibre 1.0 mm capillary tubing on a Brown-Flaming electrode puller (Sutter Instruments, San Rafael, CA). The responses were low pass filtered at 2 kHz, digitally sampled at 5–10 kHz, and analyzed using pCLAMP software (Version 7.0; Axon Instruments). The evoked postsynaptic responses were induced in CA1 stratum radiatum by stimulation (0.02 ms duration) of Schaffer collateral/commissural afferents at 0.033 Hz with a bipolar stainless steel stimulating electrode. The stimulation strength was set to elicit a response having amplitude that was 30–40% of the maximum spike-free response. fEPSPs were recorded with a glass pipette filled with 1 M NaCl (2–3 M $\Omega$  resistance) and fEPSP slope was measured from approximately 20–70% of the rising phase using a least-squares regression. The LTP was induced by HFS, at the test pulse intensity, consisting of two 1-sec trains of stimuli separated by an intertrain interval of 20 sec at 100 Hz. Depotentiation was induced by application of 10 min low-frequency trains of stimuli at 2 Hz, and the stimulation intensity was the same as the test pulse intensity. All values of residual potentiation reported here were calculated as the changes in the slope of fEPSPs measured 40 min after the end of LFS.

### **Western blotting**

Hippocampal slices were prepared and treated with HFS with or without LFS exactly as described in the electrophysiological experiments. At the end of experiments, the CA1 subregion of the hippocampal slices between the positions of the stimulating and recording electrodes was dissected out and immediately frozen on dry ice. Three to four microdissected CA1 subregions (from control, 30 min after LTP induction, 15 min after the end of LFS, 20 min after washout of CPA) were pooled together. In each experiment, an entire set of control, LTP, or depotentia-

tion pooled slices was taken from one animal. The microdissected subregions were lysed in ice-cold Tris-HCl buffer solution (TBS; pH 7.4) containing a cocktail of protein phosphatase and proteinase inhibitors (50 mM Tris-HCl, 100 mM NaCl, 15 mM sodium pyrophosphate, 50 mM sodium fluoride, 1 mM sodium orthovanadate, 5 mM EGTA, 5 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 1  $\mu\text{M}$  microcystin-LR, 1  $\mu\text{M}$  okadaic acid, 0.5% Triton X-100, 2 mM benzamidine, 60  $\mu\text{g}/\text{ml}$  aprotinin, and 60  $\mu\text{g}/\text{ml}$  leupeptin) to avoid dephosphorylation and degradation of proteins, and ground with a pellet pestle (Kontes glassware, Vineland, NJ, USA). Samples were sonicated and spun down at  $15,000 \times g$  at  $4^\circ\text{C}$  for 10 min. The supernatant was then assayed for total protein concentration using Bio-Rad Bradford Protein Assay Kit (Hercules, CA). Each sample was separated in 10% SDS-PAGE gel. Following the transfer on PVDF membranes, blots were blocked in buffer solution containing 5% milk and 0.1% Tween-20 in PBS (124 mM NaCl, 4 mM KCl, 10 mM  $\text{Na}_2\text{HPO}_4$ , and 10 mM  $\text{KH}_2\text{PO}_4$ , pH 7.2) for 1 h and then blotted for 2 h at room temperature with antibodies that recognize phosphorylated p38 MAPK (1:1000; New England BioLabs, Beverly, MA). It was then probed with HRP-conjugated secondary antibody for 1 h and developed using the ECL immunoblotting detection system (Amersham Biosciences, Buckinghamshire, UK), according to manufacturer's instructions. The immunoblots using phosphorylation site-specific antibodies were subsequently stripped and reprobed with an antibody that recognizes p38 MAPK (1:500; New England BioLabs). Immunoblots were analyzed by densitometry using Bio-profil BioLight PC software. Only film exposures that were in the linear range of the ECL reaction were used for quantification analysis.

### **Drug application**

All drugs were applied by manually switching the superfusate. Drugs were diluted from stock solutions just before application. CPA was prepared by first dissolving it in an equimolar amount of HCl as a concentrated stock and then diluting to its final concentration in aCSF. Other drugs used in this study were dissolved in distilled water. SB203580, SB239063 and CPA were purchased from Tocris Cookson (Bristol, UK).

### **Statistical analysis**

All data are expressed as means  $\pm$  SEM and the statistic significance was determined using the Mann-Whitney *U*-test or Student's *t*-test. Numbers of experiments are indicated by *n*. Probability values of  $p < 0.05$  were considered to represent significant differences.

### **Competing interests**

The authors declare that they have no competing interests.

## Authors' contributions

YCL and CCH performed the experiments and the statistical analysis, YCL, CCH, and KSH designed the study and wrote the manuscript. All authors read and approved the final manuscript.

## Acknowledgements

This work was supported by a research grant (NSC97-2752-B-006-002-PAE) from the National Science Council of Taiwan.

## References

- Bliss TV, Collingridge GL: **A synaptic model of memory: long-term potentiation in the hippocampus.** *Nature* 1993, **361(6407)**:31-39.
- Malenka RC, Bear MF: **LTP and LTD: an embarrassment of riches.** *Neuron* 2004, **44(1)**:5-21.
- Huang CC, Hsu KS: **Progress in understanding the factors regulating reversibility of long-term potentiation.** *Rev Neurosci* 2001, **12(1)**:51-68.
- Zhou Q, Poo MM: **Reversal and consolidation of activity-induced synaptic modifications.** *Trends Neurosci* 2004, **27(7)**:378-383.
- Fujii S, Saito K, Miyakawa H, Ito K, Kato H: **Reversal of long-term potentiation (depotentiation) induced by tetanus stimulation of the input to CA1 neurons of guinea pig hippocampal slices.** *Brain Res* 1991, **555(1)**:112-122.
- Huang CC, Liang YC, Hsu KS: **A role for extracellular adenosine in time-dependent reversal of long-term potentiation by low-frequency stimulation at hippocampal CA1 synapses.** *J Neurosci* 1999, **19(22)**:9728-9738.
- Sekino Y, Ito K, Miyakawa H, Kato H, Kuroda Y: **Adenosine A<sub>2</sub> antagonist inhibits induction of long-term potentiation of evoked synaptic potentials but not of the population spike in hippocampal CA1 neurons.** *Biochem Biophys Res Commun* 1991, **181(3)**:1010-1014.
- Fujii S, Sekino Y, Kuroda Y, Sasaki H, Ito K, Kato H: **8-cyclopentyltheophylline, an adenosine A<sub>1</sub> receptor antagonist, inhibits the reversal of long-term potentiation in hippocampal CA1 neurons.** *Eur J Pharmacol* 1997, **331(1)**:9-14.
- Doyle C, Hölscher C, Rowan MJ, Anwyl R: **The selective neuronal NO synthase inhibitor 7-nitro-indazole blocks both long-term potentiation and depotentiation of field EPSPs in rat hippocampal CA1 in vivo.** *J Neurosci* 1996, **16(1)**:418-424.
- Zhuo M, Zhang W, Son H, Mansuy I, Sobel RA, Seidman J, Kandel ER: **A selective role of calcineurin  $\alpha$  in synaptic depotentiation in hippocampus.** *Proc Natl Acad Sci USA* 1999, **96(8)**:4650-4655.
- Huang CC, Liang YC, Hsu KS: **Characterization of the mechanism underlying the reversal of long term potentiation by low frequency stimulation at hippocampal CA1 synapses.** *J Biol Chem* 2001, **276(51)**:48108-48117.
- Zhu Y, Pak D, Qin Y, McCormack SG, Kim MJ, Baumgart JP, Velamoor V, Auberson YP, Osten P, van Aelst L, Sheng M, Zhu JJ: **Rap2-JNK removes synaptic AMPA receptors during depotentiation.** *Neuron* 2005, **46(6)**:905-916.
- Brust TB, Cayabyab FS, Zhou N, MacVicar BA: **p38 mitogen-activated protein kinase contributes to adenosine A<sub>1</sub> receptor-mediated synaptic depression in area CA1 of the rat hippocampus.** *J Neurosci* 2006, **26(48)**:12427-12438.
- Zhu JJ, Qin Y, Zhao M, van Aelst L, Malinow R: **Ras and Rap control AMPA receptor trafficking during synaptic plasticity.** *Cell* 2002, **110(4)**:443-455.
- Huang CC, You JL, Wu MY, Hsu KS: **Rap1-induced p38 mitogen-activated protein kinase activation facilitates AMPA receptor trafficking via the GDI.Rab5 complex. Potential role in (S)-3,5-dihydroxyphenylglycine-induced long term depression.** *J Biol Chem* 2004, **279(13)**:12286-12292.
- Otmakhova NA, Lisman JE: **D<sub>1</sub>/D<sub>5</sub> dopamine receptors inhibit depotentiation at CA1 synapses via cAMP-dependent mechanism.** *J Neurosci* 1998, **18(4)**:1270-1279.
- Arai A, Kessler M, Lynch G: **The effects of adenosine on the development of long-term potentiation.** *Neurosci Lett* 1990, **119(1)**:41-44.
- Stäubli U, Chun D: **Factors regulating the reversibility of long-term potentiation.** *J Neurosci* 1996, **16(2)**:853-860.
- Han J, Lee JD, Bibbs L, Ulevitch RJ: **A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells.** *Science* 1994, **265(5173)**:808-811.
- Dunwiddie TV, Masino SA: **The role and regulation of adenosine in the central nervous system.** *Annu Rev Neurosci* 2001, **24**:31-55.
- Lee HK, Kameyama K, Huganir RL, Bear MF: **NMDA induces long-term synaptic depression and dephosphorylation of the GluR1 subunit of AMPA receptors in hippocampus.** *Neuron* 1998, **21(5)**:1151-1162.
- Bashir ZI, Jane DE, Sunter DC, Watkins JC, Collingridge GL: **Metabotropic glutamate receptors contribute to the induction of long-term depression in the CA1 region of the hippocampus.** *Eur J Pharmacol* 1993, **239(1-3)**:265-266.
- Bashir ZI, Collingridge GL: **An investigation of depotentiation of long-term potentiation in the CA1 region of the hippocampus.** *Exp Brain Res* 1994, **100(3)**:437-443.
- Zho WM, You JL, Huang CC, Hsu KS: **The group I metabotropic glutamate receptor agonist (S)-3,5-dihydroxyphenylglycine induces a novel form of depotentiation in the CA1 region of the hippocampus.** *J Neurosci* 2002, **22(20)**:8838-8849.
- Selig DK, Lee HK, Bear MF, Malenka RC: **Reexamination of the effects of MCPG on hippocampal LTP, LTD, and depotentiation.** *J Neurophysiol* 1995, **74(3)**:1075-1082.
- Robinson AJ, Dickenson JM: **Regulation of p42/p44 MAPK and p38 MAPK by the adenosine A<sub>1</sub> receptor in DDT(1)MF-2 cells.** *Eur J Pharmacol* 2001, **413(2-3)**:151-161.
- Londos C, Cooper DM, Wolff J: **Subclasses of external adenosine receptors.** *Proc Natl Acad Sci USA* 1980, **77(5)**:2551-2554.
- White TE, Dickenson JM, Alexander SP, Hill SJ: **Adenosine A<sub>1</sub>-receptor stimulation of inositol phospholipid hydrolysis and calcium mobilisation in DDT1 MF-2 cells.** *Br J Pharmacol* 1992, **106(1)**:215-221.
- Yamauchi J, Nagao M, Kaziro Y, Itoh H: **Activation of p38 mitogen-activated protein kinase by signaling through G protein-coupled receptors. Involvement of Gbetagamma and G $\alpha_{q/11}$  subunits.** *J Biol Chem* 1997, **272(44)**:27771-27777.
- Derkach VA, Oh MC, Guire ES, Soderling TR: **Regulatory mechanisms of AMPA receptors in synaptic plasticity.** *Nat Rev Neurosci* 2007, **8(2)**:101-113.
- Shepherd JD, Huganir RL: **The cell biology of synaptic plasticity: AMPA receptor trafficking.** *Annu Rev Cell Dev Biol* 2007, **23**:613-643.
- Shi S, Hayashi Y, Esteban JA, Malinow R: **Subunit-specific rules governing AMPA receptor trafficking to synapses in hippocampal pyramidal neurons.** *Cell* 2001, **105(3)**:331-343.
- Hayashi Y, Shi SH, Esteban JA, Piccini A, Poncer JC, Malinow R: **Driving AMPA receptors into synapses by LTP and CaMKII: requirement for GluR1 and PDZ domain interaction.** *Science* 2000, **287(5461)**:2262-2267.
- Kandler K, Katz LC, Kauer J: **Focal photolysis of caged glutamate produces long-term depression of hippocampal glutamate receptors.** *Nat Neurosci* 1998, **1(2)**:119-123.
- Lüthi A, Chittajallu R, Duprat F, Palmer MJ, Benke TA, Kidd FL, Henley JM, Isaac JT, Collingridge GL: **Hippocampal LTD expression involves a pool of AMPARs regulated by the NSF-GluR2 interaction.** *Neuron* 1999, **24(2)**:389-399.
- Zhou Q, Tao HW, Poo MM: **Reversal and stabilization of synaptic modifications in a developing visual system.** *Science* 2003, **300(5627)**:1953-1957.
- Schulte G, Fredholm BB: **Signaling from adenosine receptors to mitogen-activated protein kinases.** *Cell Signal* 2003, **15(9)**:813-827.